stockrow
Friday 6 November 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
44.89
6.02
+15.49%
Follow EWTX
Alert me
Edgewise Therapeutics, Inc. (EWTX) Debt to equity
Edgewise Therapeutics, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 0.0× (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| TNGX Tango Therapeutics, Inc. compare | 0.0× |
| EWTX Edgewise Therapeutics, Inc. | 0.0× |
| ABCL AbCellera Biologics Inc. compare | 0.0× |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.0× |
| RLAY Relay Therapeutics, Inc. compare | 0.0× |
| XENE Xenon Pharmaceuticals Inc. compare | 0.0× |
| DFTX Definium Therapeutics, Inc. compare | 0.0× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 0.1× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 0.4× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)